To clarify the role of increased PD-1 expression that we found especially when the cells were treated with the antibodies against PD-1 (Nivolumab) and PD-L1 (10_12), we decided to analyze the cell extracts of tumor cells treated for 72 h with PD-1 or PD-L1 agonists (PD-1/Fc or PD-L1/Fc chimeric proteins) for comparing their effects to those shown by their respective antagonists, Nivolumab or 10_12 mAbs. The gene discussed is CD274; the disease is neoplasm.